Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06358196
Other study ID # CESAH
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 1, 2024
Est. completion date April 30, 2026

Study information

Verified date April 2024
Source Pavol Jozef Safarik University
Contact Jakub Gazda, MD, PhD
Phone +421911115288
Email jakub.gazda@upjs.sk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Alcohol-associated hepatitis is a clinical syndrome distinct from steatohepatitis or liver cirrhosis. It is associated with high mortality and characterized by an absence of effective treatment, while corticosteroids, which are currently used as the first-line treatment are effective only in a subpopulation of patients and only on 28-days survival - their effect on survival does not last beyond this interval. The proposed study is a complex exploratory study of alcohol-associated hepatitis with several epidemiology- and prognosis-related aims.


Description:

Alcohol-associated hepatitis is a clinical syndrome distinct from steatohepatitis or liver cirrhosis. It is associated with high mortality and characterized by an absence of effective treatment, while corticosteroids, which are currently used as the first-line treatment are effective only in a subpopulation of patients and only on 28-days survival - their effect on survival does not last beyond this interval. The proposed study is a complex exploratory study of alcohol-associated hepatitis with the following aims: (1) to estimate the standardized annual incidence of (severe) AH in the Kosice Urban Area, (2) to estimate the threshold of alcohol consumption associated with (an increased risk of) developing AH, (3) to compare the diagnostic accuracy of NIAAA vs NIAAAm-CRP against liver biopsy, (4) to perform a head-to-head comparison of widely-accepted prognostic models and to develop prognostic models, (5) to observe prognosis of nonsevere alcohol-associated hepatitis, (6) to observe the evolution of severe alcohol-associated hepatitis, (7) to describe the association of hypothalamus-hypopituitary-adrenal axis and Gut-Liver Microbiome Axis and Prognosis of Alcohol-associated Hepatitis, (8) to describe the adherence to outpatient psychiatric management and its impact on long-term prognosis, (9) to perform a longitudinal evaluation of nutritional status, its changes, and its impact on long-term prognosis. Study Design This is a multicenter observational study of patients with alcohol-associated hepatitis. The total trial duration for each subject is approximately 53 weeks. This includes a screening period of a maximum of one week (7 days), during which the diagnosis of AH will be confirmed, followed by a 52 weeks (365 days) observational period. Diagnosis of Alcohol-associated Hepatitis The diagnosis of alcohol-associated hepatitis will be established using the National Institute on Alcohol Abuse and Alcoholism (NIAAA) diagnostic criteria: onset of jaundice within prior 8 weeks; ongoing consumption of >40 (females) or >60 (males) g alcohol/day ≥ 6 months, with less than 60 days of abstinence before the onset of jaundice; aspartate aminotransferase >0.83µkat/L (but less than 6.64 µkat/L), AST/ALT > 1.5, and total serum bilirubin > 51.3 mmol/L. NIAAA definitions for AH differentiate between possible AH (clinically diagnosed with potential confounding factors), in which transjugular liver biopsy is indicated, probable AH (clinically diagnosed without potential confounding factors), and definite AH (clinically diagnosed and biopsy proven). Considerations Regarding Patient Admission and Discharge Local standards dictate that patients with acute liver injury or acute liver failure are typically admitted to the 2nd Department of Internal Medicine, which specializes in gastroenterology and hepatology. This admission is carried out to facilitate further differentiation and provide specific treatment tailored to their condition. However, patients have the option to decline admission and, in such cases, will be discharged and managed as outpatients. Once patients provide their consent to participate in the study, the screening period will commence. This screening phase may have a variable duration and will persist until a definitive diagnosis of AH is confirmed (either with or without results from histopathological evaluation of liver specimen). The observational period will begin as soon as the diagnosis of AH will be confirmed with specific treatment in cases of sAH. Patients diagnosed with nAH will undergo evaluation for potential discharge starting on Day 4 of the observational period. In contrast, patients with sAH will be assessed for their therapeutic response, as well as for the possibility of discharge, using the Lille score on Day 7 of the observational period. If patients do not respond to treatment, it will be discontinued. For patients who respond positively to treatment, it will be sustained until Day 28 of the observational period. Following this period, treatment will be gradually tapered down by reducing the dosage by half each week, continuing for a total of three weeks. The decision to discharge patients will be based on the absence of significant complications or serious events, such as gastrointestinal bleeding, overt hepatic encephalopathy, infection, kidney injury, and similar conditions. Similarly, if any of these events occur after discharge, patients will be promptly readmitted and receive appropriate treatment. Patients will be offered psychiatric inpatient or outpatient care before discharge.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date April 30, 2026
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: • Patients older than 18 years with acute liver injury / acute liver failure with later confirmation of the AH diagnosis according to the NIAAA diagnostic criteria [14] who provided written informed consents for admission and further differentiation, and for study participation Exclusion Criteria: - Patients not confirmed to have alcohol-associated hepatitis - Patients with malignancies (specifically those with life-expectancy limitation) - Patients who withdrew consent for study participation

Study Design


Locations

Country Name City State
Slovakia Pavol Jozef Safarik University Kosice

Sponsors (6)

Lead Sponsor Collaborator
Pavol Jozef Safarik University Hospital Agel Kosice-Saca, L Pasteur University Hospital, Technical University in Kosice, University of Roma La Sapienza, Western University

Country where clinical trial is conducted

Slovakia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Standardized annual incidence of (severe) alcoholic hepatitis in the Kosice Urban Area Number of patients with (severe) alcoholic hepatitis 1 year
Secondary Threshold of alcohol consumption associated with (an increased risk of) developing AH Grams of alcohol per week Baseline
Secondary Diagnostic accuracy of NIAAA and NIAAAm-CRP Accuracy against liver biopsy Baseline
Secondary Prognostic performance of Maddrey, MELD, MELD-Na, MELD 3.0, GAHS, ABIC, Lille score Discriminatory characteristics (area under receiver operating characteristics curve) and calibration (calibration belts) with respect to 30 and 90 days mortality Baseline, Days 2, 4, 7
Secondary Prognostic performance of SOFA and CLIF-C Discriminatory characteristics (area under receiver operating characteristics curve) and calibration (calibration belts) with respect to 30 and 90 days mortality Baseline, Days 2, 4, 7
Secondary An update of Maddrey, MELD, MELD-Na, MELD 3.0, GAHS, ABIC, Lille score To reevaluate independent variables in prognostic models aiming for improved discriminatory characteristics (area under receiver operating characteristics curve) and calibration (calibration belts) Baseline
Secondary Alternative to Lille model Regression model with 30 day mortality as exploratory variable Baseline, Day 2
Secondary Prognostic model for 90 day survival Regression model with 90 day mortality as exploratory variable Baseline
Secondary Uper limit of MELD or Maddrey scores beyond which patients no longer derive any therapeutic benefit from corticosteroid treatment Upper threshold value of MELD and Maddrey scores associated with increased risk of mortality Baseline
Secondary Natural course of nonsevere alcoholic hepatitis Mortality (and prevalence of ascites, hepatic encephalopathy, variceal bleeding, bacterial infection, acute kidney injury and proportion of patients with progression to severe alcoholic hepatitis) 1 year
Secondary Natural course of severe alcoholic hepatitis Mortality (and prevalence of ascites, hepatic encephalopathy, variceal bleeding, bacterial infection, acute kidney injury and proportion of patients with progression to severe alcoholic hepatitis or with withdrawal syndrome, or with relapse of alcohol drinking) 1 year
Secondary Risk score for bacterial infection before corticosteroid treatment in patients with alcoholic hepatitis 30-days regression model for infection as exploratory variable Baseline
Secondary Distinguishing sterile Inflammation from infection in alcoholic hepatitis Ratio of inflammatory markers 1 year
Secondary GUT microbiome and treatment response in alcoholic hepatitis Differences in GUT microbiome between corticosteroid responders and nonresponders Baseline, Day 90
Secondary Hypothalamus-pituitary-adrenal axis and treatment response in alcoholic hepatitis Differences in cortisol levels between corticosteroid responders and nonresponders Baseline, Day 28
Secondary Adherence to outpatient psychiatric management Proportion of patients adhering to outpatient psychiatric management 1 year
Secondary Nutritional status and treatment response in alcoholic hepatitis Differences in nutritional status between corticosteroid responders and nonresponders Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04066179 - Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients. N/A
Completed NCT03732586 - Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT00962442 - N-Acetylcysteine in Severe Acute Alcoholic Hepatitis Phase 3
Not yet recruiting NCT06307522 - MRG-001 in Patients With Alcoholic Hepatitis Phase 2
Recruiting NCT05018481 - HA35 Moderate Alcoholic Hepatitis (AH) Study Early Phase 1
Completed NCT04544020 - Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Recruiting NCT04088370 - Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Completed NCT04235855 - EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication? N/A
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT00851981 - Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease Phase 2
Completed NCT04084522 - Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis N/A
Completed NCT05840640 - Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis Phase 4
Recruiting NCT03069300 - N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis Phase 3
Terminated NCT02039219 - Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Phase 2
Completed NCT02019056 - Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Phase 2
Completed NCT01245257 - Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis N/A
Completed NCT00388323 - Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human N/A
Recruiting NCT03845205 - Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH N/A
Recruiting NCT03703674 - GCSF in Alcoholic Hepatitis Phase 4